Switch theme
Sign up to access all valuation multiples
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company’s drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
2001
5
LTM Revenue $11.1M
LTM EBITDA -$36.0M
$316M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
PYC Therapeutics has a last 12-month revenue of $11.1M and a last 12-month EBITDA of -$36.0M.
In the most recent fiscal year, PYC Therapeutics achieved revenue of n/a and an EBITDA of -$23.5M.
PYC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See PYC Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$14.3M | -$23.5M | XXX | XXX | XXX |
| EBITDA Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Profit | -$8.7M | -$14.3M | XXX | XXX | XXX |
| Net Margin | NaN% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, PYC Therapeutics's stock price is AUD 1 (or $1).
PYC Therapeutics has current market cap of AUD 551M (or $346M), and EV of AUD 503M (or $316M).
See PYC Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $316M | $346M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, PYC Therapeutics has market cap of $346M and EV of $316M.
PYC Therapeutics's trades at 28.5x LTM EV/Revenue multiple, and -8.8x LTM EBITDA.
Analysts estimate PYC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for PYC Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $316M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -10.1x | XXX | XXX | XXX |
| P/E | -12.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -11.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPYC Therapeutics's NTM/LTM revenue growth is -2%
PYC Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $7.6M for the same period.
Over next 12 months, PYC Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate PYC Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for PYC Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 64% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $7.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PYC Therapeutics acquired XXX companies to date.
Last acquisition by PYC Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . PYC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was PYC Therapeutics founded? | PYC Therapeutics was founded in 2001. |
| Where is PYC Therapeutics headquartered? | PYC Therapeutics is headquartered in Australia. |
| How many employees does PYC Therapeutics have? | As of today, PYC Therapeutics has 5 employees. |
| Is PYC Therapeutics publicy listed? | Yes, PYC Therapeutics is a public company listed on ASX. |
| What is the stock symbol of PYC Therapeutics? | PYC Therapeutics trades under PYC ticker. |
| When did PYC Therapeutics go public? | PYC Therapeutics went public in 2005. |
| Who are competitors of PYC Therapeutics? | Similar companies to PYC Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of PYC Therapeutics? | PYC Therapeutics's current market cap is $346M |
| What is the current revenue of PYC Therapeutics? | PYC Therapeutics's last 12-month revenue is $11.1M. |
| What is the current EBITDA of PYC Therapeutics? | PYC Therapeutics's last 12-month EBITDA is -$36.0M. |
| What is the current EV/Revenue multiple of PYC Therapeutics? | Current revenue multiple of PYC Therapeutics is 28.5x. |
| What is the current EV/EBITDA multiple of PYC Therapeutics? | Current EBITDA multiple of PYC Therapeutics is -8.8x. |
| Is PYC Therapeutics profitable? | Yes, PYC Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
